Triclabendazole is used to treat fascioliasis, an infection caused by the liver fluke parasite, Fasciola hepatica. Infections with a liver fluke usually occur after eating contaminated water plants, such as watercress or algae, or animals that eat these p + some more technical info Triclabendazole is a chlorinated benzimidazole derivative with high lipophilicity that concentrates in hepatic tissue and disrupts fluke metabolism and tegument integrity; it is rapidly absorbed after oral administration and is metabolized primarily to an active sulfoxide and subsequently to a sulfone, both of which contribute to antiparasitic activity. Analytical characterization normally uses HPLC with UV detection for assay and related-substance profiling, combined with MS for impurity identification; physicochemical properties important to formulation include low aqueous solubility, thermal stability under controlled conditions, and a crystalline solid state amenable to micronization for oral dosage forms.
Parent: Triclabendazole
Parent: Triclabendazole
Parent: Triclabendazole
Parent: Triclabendazole
Parent: Triclabendazole
Parent: Triclabendazole
Parent: Triclabendazole
Typical quality specifications for triclabendazole active pharmaceutical ingredient include assay 98.0 to 102.0 percent by HPLC, loss on drying not greater than 0.5 percent, and water content under 0.5 percent. Related compounds and typical control limits are expressed as percentage of the API by area percent in the validated HPLC method and may be set as follows: triclabendazole sulfoxide up to 0.50 percent, triclabendazole sulfone up to 0.50 percent, any single known impurity not greater than 0.30 percent, any unidentified impurity not greater than 0.10 percent, and total impurities not exceeding 1.0 percent. Residual solvents and elemental impurities are controlled per ICH Q3C and Q3D respectively, for example class II solvents limitations and heavy metals typically below 20 parts per million, with final acceptance criteria defined in the product master file and regulatory dossier.
Triclabendazole is the treatment of choice for human and veterinary fascioliasis caused by Fasciola hepatica; it paralyzes and damages the parasite tegument and metabolic pathways, leading to clearance of adult and immature flukes in the liver and biliary system.
No, albendazole and triclabendazole are different compounds within the broader benzimidazole class; albendazole has broader activity against nematodes and some cestodes, whereas triclabendazole is particularly active against liver flukes and differs in chemical structure, pharmacokinetics, and primary metabolites.
Triclabendazole is the preferred medication for killing liver flukes in humans because of its proven efficacy against Fasciola species; other agents have been used historically or in specific contexts, but triclabendazole provides the best-documented clinical cure rates for fascioliasis.
No, mebendazole is a separate benzimidazole anthelmintic with primary activity against intestinal nematodes; mebendazole is not equivalent to triclabendazole in spectrum or efficacy against liver flukes.
